No Picture
News

Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 29, 2022 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of… Click here to view original post… […]

No Picture
News

More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a ‘near certainty’

While Sarepta has three antisense oligonucleotide therapies approved — albeit not without controversy — for Duchenne muscular dystrophy, it has been working on a long-term treatment in the form of a gene therapy. After posting positive results for its Roche-partnered gene therapy, dubbed SRP-9001, earlier this month, the Cambridge, MA-based…… Click here to view original post… […]

No Picture
News

Covid-19 roundup: Moderna, US sign contract for autumn booster doses; Enanta touts PhI results for its antiviral

The US government has placed a contract for 66 million doses of Moderna’s Covid-19 vaccine booster candidate, and the deal could balloon to another 234 million doses. The contract includes up to $1.74 billion for Moderna to manufacture and deliver the doses of the bivalent vaccine candidate, dubbed mRNA-1273.222. The… Click here to view original post… […]

No Picture
News

Pediatric Medical Centers Improve the Efficiency of Investigator-Initiated, Multi-Site, Collaborative Research with TriNetX

CAMBRIDGE, Mass., July 29, 2022 /PRNewswire/ — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced the inaugural members of the Pediatric Collaboratory Network (PCN), comprised of Children’s… Click here to view original post… […]